ArticleGlycoconjugate journal2026
Identification of mitochondrial associated genes as diagnostic biomarkers for basal cell carcinoma: Comprehensive bioinformatics analysis and experimental validation.
Article in Glycoconjugate journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of our research was to explore and validate the diagnostic value of mitochondria-related genes (MRGs) in basal cell carcinoma (BCC). The differentially expressed MRGs in BCC were identified based on the GSE39612, GSE42109 and GSE7553 training sets and the GSE53462 validation set, and the PPI network was drawn. The potential signature genes in BCC were screened by LASSO, RF and SVM-RFE. Besides, the performance of the signature genes was evaluated and a nomogram was constructed. Moreover, immunoinfiltration, drug prediction and transcriptional regulation of these signature genes were also analyzed. Finally, qRT-PCR was employed to measure the expression of signature genes in clinical tissues and BCC cells. 1699 DEGs were obtained from the training set. Then, taking the intersection of DEGs, WGCNA module genes and MRGs, 36 DEGs-MRGs were obtained. Six potential signature genes in BCC, including ACADL, BCL2L2, CHCHD7, LDHB, NT5DC2, and PDK4, were obtained through LASSO, RF, and SVM-RFE. Nomogram and validation analysis confirmed that these 6 genes have ideal predictive power in BCC. In addition, 6 signature genes were significantly associated with macrophages and interacted with pyruvic acid, sodium chromate, perfluoroheptanoic acid and other drugs. Finally, qRT-PCR analysis showed that the expression trend of these 6 signature genes in clinical tissues and BCC cells was consistent with the results of bioinformatics analysis. ACADL, BCL2L2, CHCHD7, LDHB, NT5DC2 and PDK4 are potential diagnostic signature genes of BCC.
Indexed as
Identifiers
41677970What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.